首页 | 本学科首页   官方微博 | 高级检索  
     

血清白蛋白与球蛋白比值联合血小板与淋巴细胞比值对AECOPD患者出院后1年内再入院的预测价值
引用本文:李 彬,张 静,林 琦,陈自行,杨士芳. 血清白蛋白与球蛋白比值联合血小板与淋巴细胞比值对AECOPD患者出院后1年内再入院的预测价值[J]. 现代生物医学进展, 2023, 0(24): 4682-4686
作者姓名:李 彬  张 静  林 琦  陈自行  杨士芳
作者单位:南方医科大学附属广东省人民医院(广东省医学科学院)老年呼吸二科 广东 广州 510000;南方医科大学附属广东省人民医院(广东省医学科学院)老年呼吸一科 广东 广州 510000;南方医科大学附属广东省人民医院(广东省医学科学院)呼吸与危重症医学科 广东 广州 510000
基金项目:广东省自然科学基金项目(2018A0303130342)
摘    要:摘要 目的:分析慢性阻塞性肺疾病急性加重期(AECOPD)患者出院后1年内再入院的影响因素,同时探讨血清白蛋白与球蛋白比值(AGR)联合血小板与淋巴细胞比值(PLR)对AECOPD患者出院后1年内再入院的预测价值。方法:选取2018年5月~2021年10月期间广东省人民医院收治的261例AECOPD患者,根据出院后1年内是否再入院分为再入院组(n=96)和无再入院组(n=165)。对比两组AGR、PLR。采用单因素及多因素Logistic回归分析AECOPD患者出院后1年内再入院的影响因素。采用受试者工作特征(ROC)曲线分析AGR、PLR对AECOPD患者出院后1年内再入院的预测价值。结果:再入院组的AGR低于无再入院组,PLR高于无再入院组(P<0.05)。AECOPD患者出院后1年内再入院与ADL评分、日均中低强度身体活动时间、家庭氧疗、入院前1年急性加重次数、FEV1%Pred、抗生素使用时间有关(P<0.05)。多因素Logistic回归分析显示:日均中低强度身体活动时间<2 h、入院前1年急性加重次数≥2次、FEV1%Pred<50、AGR偏低、PLR偏高是AECOPD患者出院后1年内再入院的危险因素(P<0.05)。ROC曲线分析显示:AGR、PLR联合预测AECOPD患者出院后1年内再入院的曲线下面积(AUC)大于AGR、PLR单独预测。结论:AGR联合PLR对AECOPD患者出院后1年内再入院的预测价值较高。日均中低强度身体活动时间<2 h、入院前1年急性加重次数≥2次、FEV1%Pred<50、AGR偏低、PLR偏高是AECOPD患者出院后1年内再入院的危险因素。

关 键 词:白蛋白与球蛋白比值;血小板与淋巴细胞比值;慢性阻塞性肺疾病急性加重期;再入院;预测价值
收稿时间:2023-05-06
修稿时间:2023-05-30

Predictive Value of Serum Albumin to Globulin Ratio Combined with Platelet to Lymphocyte Ratio for Readmission within 1 Year after Discharge of Patients with AECOPD
Abstract:ABSTRACT Objective: To analyze the influencing factors of readmission within 1 year after discharge of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and to explore the predictive value of serum albumin to globulin ratio (AGR) combined with platelet to lymphocyte ratio (PLR) for readmission within 1 year after discharge of patients with AECOPD at the same time. Methods: 261 patients with AECOPD who were admitted to Guangdong Provincial People''s Hospital from May 2018 to October 2021 were selected, and they were divided into readmission group(n=96) and non readmission group(n=165) based on whether they were readmission within 1 year after discharge. The AGR and PLR were compared between the two groups, and the influencing factors of readmission within 1 year after discharge of patients with AECOPD were analyzed by univariate and multivariate Logistic regression analysis. The predictive value of AGR and PLR for readmission within 1 year after discharge of patients with AECOPD was analyzed by the receiver operating characteristic (ROC) curve. Results: The AGR of the readmission group was lower than that of the non readmission group, while the PLR was higher than that of the non readmission group (P<0.05). The readmission within 1 year after discharge of patients with AECOPD was related to ADL scores, daily average time of moderate to low intensity physical activity, home oxygen therapy, number of acute exacerbations in the first year before admission, FEV1% Pred, time of use antibiotic(P<0.05). Multivariate Logistic regression analysis showed that daily average time of moderate to low intensity physical activity less than 2 h, number of acute exacerbations in the first year before admission greater than or equal 2 times, FEV1%Pred less than 50, low AGR, and high PLR were risk factors for readmission within 1 year after discharge of patients with AECOPD(P<0.05). ROC curve analysis showed that the area under the curve (AUC) predicted by the combination of AGR and PLR for readmission within 1 year after discharge of patients with AECOPD was greater than that predicted by AGR and PLR alone. Conclusion: The predictive value of AGR combine with PLR for readmission within 1 year after discharge of patients with AECOPD are higer. daily average time of moderate to low intensity physical activity less than 2 h, number of acute exacerbations in the first year before admission greater than or equal 2 times, FEV1%Pred less than 50, low AGR, and high PLR were risk factors for readmission within 1 year after discharge of patients with AECOPD.
Keywords:Albumin to globulin ratio   Platelet to lymphocyte ratio   AECOPD   Readmission   Predictive value
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号